^
    almost3years
    Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov)
    P1, N=9, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2036 --> Jan 2023
    Trial completion • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells
    almost4years
    Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=14 --> 9
    Enrollment closed • Enrollment change
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells
    over5years
    A Phase 1 Clinical Trial Using Armored GPC3-Car T Cells for Children with Relapsed/ Refractory Liver Tumors (ASGCT 2020)
    The initial results from this clinical trial show that GPC3-CAR T cells are well tolerated and have anti-tumor activity in children with liver tumors.
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3)
    |
    GLYCAR T cells